{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:41:42Z","timestamp":1784900502346,"version":"3.55.0"},"reference-count":37,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,10]]},"DOI":"10.20945\/2359-4292-2023-0502","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T12:21:25Z","timestamp":1712838085000},"source":"Crossref","is-referenced-by-count":10,"title":["Diagnosis of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM)"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"Andrea","family":"Glezer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-8548","authenticated-orcid":false,"given":"Heraldo Mendes","family":"Garmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-3192","authenticated-orcid":false,"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7272-9552","authenticated-orcid":false,"given":"Manoel","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-4813","authenticated-orcid":false,"given":"Paula Cond\u00e9 Lamparelli","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania dos Santos Nunes","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-344X","authenticated-orcid":false,"given":"Ana Carolina Japur de S\u00e1","family":"Rosa-e-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-8528","authenticated-orcid":false,"given":"Gustavo Arantes Rosa","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-5593","authenticated-orcid":false,"given":"Cristina Laguna","family":"Benetti-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-0206","authenticated-orcid":false,"given":"Andrea Prestes","family":"N\u00e1cul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20240411082120_B1","author":"Snyder","year":"2018","unstructured":"1 Snyder PJ. Clinical manifestations and evaluation of hyperprolactinemia. 2018 [cited 2022 Jan 20]. Available from: https:\/\/www.medilib.ir\/uptodate\/show\/6638","journal-title":"Clinical manifestations and evaluation of hyperprolactinemia"},{"issue":"8","key":"key20240411082120_B2","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2009-0177","article-title":"Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia","volume":"94","author":"Kars","year":"2009","unstructured":"2 Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729-34. doi: 10.1210\/jc.2009-0177","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20240411082120_B3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","unstructured":"3 Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-82. doi: 10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20240411082120_B4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","article-title":"Nonfunctioning pituitary tumors and pituitary incidentalomas","volume":"37","author":"Molitch","year":"2008","unstructured":"4 Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am. 2008;37(1):151-71, xi. doi: 10.1016\/j.ecl.2007.10.011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"key20240411082120_B5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","unstructured":"5 Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"key20240411082120_B6","volume-title":"South Dartmouth","author":"Glezer","year":"2022","unstructured":"6 Glezer A, Bronstein MD. Hyperprolactinemia. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext. South Dartmouth: MDText.com; 2022 [cited 2022 Feb 26]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK278984\/"},{"issue":"1","key":"key20240411082120_B7","first-page":"3","article-title":"Prolactin biology and laboratory measurement: an update on physiology and current analytical issues","volume":"39","author":"Saleem","year":"2018","unstructured":"7 Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018;39(1):3-16.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"key20240411082120_B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the diagnostic evaluation of hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","unstructured":"8 Vilar L, Vilar CF, Lyra R, Freitas MC. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109(1):7-19. doi: 10.1159\/000499694","journal-title":"Neuroendocrinology"},{"issue":"2","key":"key20240411082120_B9","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","unstructured":"9 Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101290. doi: 10.1016\/j.beem.2019.101290. Epub 2019 Jul 10. PMID: 31326373.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"key20240411082120_B10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar","year":"2008","unstructured":"10 Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31(5):436-44. doi: 10.1007\/BF03346388","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"key20240411082120_B11","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","unstructured":"11 Raappana A, Koivukangas J, Ebeling T, Piril\u00e4 T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95(9):4268-75. doi: 10.1210\/jc.2010-0537","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20240411082120_B12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11102-020-01085-5","article-title":"AIP variant causing familial prolactinoma","volume":"24","author":"Carty","year":"2021","unstructured":"12 Carty DM, Harte R, Drummond RS, Ward R, Magid K, Collier D, et al. AIP variant causing familial prolactinoma. Pituitary. 2021;24(1):48-52. doi: 10.1007\/s11102-020-01085-5","journal-title":"Pituitary"},{"issue":"2","key":"key20240411082120_B13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.20945\/2359-3997000000032","article-title":"Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism","volume":"62","author":"Vilar","year":"2018","unstructured":"13 Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236-63. doi: 10.20945\/2359-3997000000032","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"key20240411082120_B14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40618-020-01338-x","article-title":"The prevalence of silent acromegaly in prolactinomas is very low","volume":"44","author":"Bona","year":"2021","unstructured":"14 Bona C, Prencipe N, Jaffrain-Rea ML, Carosi G, Lanzi R, Ambrosio MR, et al. The prevalence of silent acromegaly in prolactinomas is very low. J Endocrinol Invest. 2021;44(3):531-9. doi: 10.1007\/s40618-020-01338-x","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"key20240411082120_B15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1530\/EJE-11-1119","article-title":"The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases","volume":"166","author":"Wang","year":"2012","unstructured":"15 Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, et al. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol. 2012;166(5):797-802. doi: 10.1530\/EJE-11-1119","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"key20240411082120_B16","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","unstructured":"16 Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019;8(12):2203. doi: 10.3390\/jcm8122203","journal-title":"J Clin Med"},{"issue":"4","key":"key20240411082120_B17","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","unstructured":"17 Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523-631. doi: 10.1152\/physrev.2000.80.4.1523","journal-title":"Physiol Rev"},{"issue":"5","key":"key20240411082120_B18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1515\/cclm-2017-0644","article-title":"Serum prolactin levels across pregnancy and the establishment of reference intervals","volume":"56","author":"Hu","year":"2018","unstructured":"18 Hu Y, Ding Y, Yang M, Xiang Z. Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab Med. 2018;56(5):838-42. doi: 10.1515\/cclm-2017-0644","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"key20240411082120_B19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hdi.12489","article-title":"Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis","volume":"21","author":"Lo","year":"2017","unstructured":"19 Lo JC, Beck GJ, Kaysen GA, Chan CT, Kliger AS, Rocco MV, et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial Int. 2017;21(2):190-6. doi: 10.1111\/hdi.12489","journal-title":"Hemodial Int"},{"issue":"1","key":"key20240411082120_B20","first-page":"255","article-title":"Neuroendocrine regulation of lactation and milk production","volume":"5","author":"Crowley","year":"2015","unstructured":"20 Crowley WR. Neuroendocrine regulation of lactation and milk production. Compr Physiol. 2015;5(1):255-91. doi: 10.1002\/cphy.c140029","journal-title":"Compr Physiol"},{"issue":"7","key":"key20240411082120_B21","first-page":"OC30","article-title":"Correlation of serum prolactin level to Child Pugh scoring system in cirrhosis of liver","volume":"11","author":"Balakrishnan","year":"2017","unstructured":"21 Balakrishnan CH, Rajeev H. Correlation of serum prolactin level to Child Pugh scoring system in cirrhosis of liver. J Clin Diagn Res. 2017;11(7):OC30-3. doi: 10.7860\/JCDR\/2017\/24730.10273","journal-title":"J Clin Diagn Res"},{"issue":"12","key":"key20240411082120_B22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1507\/endocrj.K10E-215","article-title":"The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism","volume":"57","author":"Hekimsoy","year":"2010","unstructured":"22 Hekimsoy Z, Kafes\u00e7iler S, G\u00fc\u00e7l\u00fc F, Ozmen B. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J. 2010;57(12):1011-5. doi: 10.1507\/endocrj.k10e-215","journal-title":"Endocr J"},{"issue":"2","key":"key20240411082120_B23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2265.2003.01694.x","article-title":"Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization","volume":"58","author":"Raber","year":"2003","unstructured":"23 Raber W, Gessl A, Nowotny P, Vierhapper H. Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin Endocrinol. 2003;58(2):185-91. doi: 10.1046\/j.1365-2265.2003.01694.x","journal-title":"Clin Endocrinol"},{"issue":"1","key":"key20240411082120_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.13245","article-title":"PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude","volume":"86","author":"Kyritsi","year":"2017","unstructured":"24 Kyritsi EM, Dimitriadis GK, Kyrou I, Kaltsas G, Randeva HS. PCOS remains a diagnosis of exclusion: a concise review of key endocrinopathies to exclude. Clin Endocrinol (Oxf). 2017;86(1):1-6. doi: 10.1111\/cen.13245","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"key20240411082120_B25","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12961","article-title":"The value of prolactin in predicting prolactin\u03bfma in hyperprolactinaemic polycystic ovarian syndrome","volume":"48","author":"Kyritsi","year":"2018","unstructured":"25 Kyritsi EM, Dimitriadis GK, Angelousi A, Mehta H, Shad A, Mytilinaiou M, et al. The value of prolactin in predicting prolactin\u03bfma in hyperprolactinaemic polycystic ovarian syndrome. Eur J Clin Invest. 2018;48(7):e12961. doi: 10.1111\/eci.12961","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"key20240411082120_B26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2265.2011.04226.x","article-title":"Disconnection hyperprolactinaemia in nonadenomatous sellar\/parasellar lesions practically never exceeds 2000 mU\/l","volume":"76","author":"Korevaar","year":"2012","unstructured":"26 Korevaar T, Wass JA, Grossman AB, Karavitaki N. Disconnection hyperprolactinaemia in nonadenomatous sellar\/parasellar lesions practically never exceeds 2000 mU\/l. Clin Endocrinol (Oxf). 2012;76(4):602-3. doi: 10.1111\/j.1365-2265.2011.04226.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key20240411082120_B27","doi-asserted-by":"crossref","first-page":"g5390","DOI":"10.1136\/bmj.g5390","article-title":"Diagnosis and management of prolactinomas and non-functioning pituitary adenomas","volume":"349","author":"Rogers","year":"2014","unstructured":"27 Rogers A, Karavitaki N, Wass JA. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014;349:g5390. doi: 10.1136\/bmj.g5390","journal-title":"BMJ"},{"issue":"3","key":"key20240411082120_B28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat","year":"2004","unstructured":"28 Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613-9. doi: 10.1002\/cncr.20412","journal-title":"Cancer"},{"issue":"6","key":"key20240411082120_B29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2265.2007.02990.x","article-title":"What is the natural history of nonoperated nonfunctioning pituitary adenomas?","volume":"67","author":"Karavitaki","year":"2007","unstructured":"29 Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf). 2007;67(6):938-43. doi: 10.1111\/j.1365-2265.2007.02990.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20240411082120_B30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ejendo\/lvad070","article-title":"Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium","volume":"189","author":"Hamblin","year":"2023","unstructured":"30 Hamblin R, Fountas A, Lithgow K, Loughrey PB, Bonanos E, Shinwari SK, et al. Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium. Eur J Endocrinol. 2023;189(1):87-95. doi: 10.1093\/ejendo\/lvad070","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20240411082120_B31","first-page":"1711","article-title":"Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up","volume":"81","author":"Feigenbaum","year":"1996","unstructured":"31 Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB. Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab. 1996;81(5):1711-9. doi: 10.1210\/jcem.81.5.8626821","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20240411082120_B32","first-page":"153","article-title":"Clinical presentations of drug-induced hyperprolactinaemia: a literature review","volume":"37","author":"Junqueira","year":"2023","unstructured":"32 Junqueira DR, Bennett D, Huh SY, Casa\u00f1as I Comabella C. Clinical presentations of drug-induced hyperprolactinaemia: a literature review. Pharmaceut Med. 2023;37(2):153-66. doi: 10.1007\/s40290-023-00462-2","journal-title":"Pharmaceut Med"},{"issue":"1","key":"key20240411082120_B33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cen.13156","article-title":"The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS)","volume":"86","author":"Soto-Pedre","year":"2017","unstructured":"33 Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 2017;86(1):60-7. doi: 10.1111\/cen.13156","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"key20240411082120_B34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11102-008-0106-6","article-title":"Drugs and prolactin","volume":"11","author":"Molitch","year":"2008","unstructured":"34 Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-18. doi: 10.1007\/s11102-008-0106-6","journal-title":"Pituitary"},{"issue":"3","key":"key20240411082120_B35","first-page":"42","article-title":"Strategies for managing medication-induced hyperprolactinemia","volume":"17","author":"Navy","year":"2018","unstructured":"35 Navy H, Gardner K. Strategies for managing medication-induced hyperprolactinemia. Curr Psychiatry. 2018;17(3):42-6.","journal-title":"Curr Psychiatry"},{"issue":"3","key":"key20240411082120_B36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12020-014-0259-1","article-title":"Women with prolactinomas presented at the postmenopausal period","volume":"47","author":"Shimon","year":"2014","unstructured":"36 Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A. Women with prolactinomas presented at the postmenopausal period. Endocrine. 2014;47(3):889-94. doi: 10.1007\/s12020-014-0259-1","journal-title":"Endocrine"},{"key":"key20240411082120_B37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.maturitas.2021.06.014","article-title":"Hyperprolactinemia after menopause: diagnosis and management","volume":"151","author":"Auriemma","year":"2021","unstructured":"37 Auriemma RS, Pirchio R, Pivonello R, Colao A. Hyperprolactinemia after menopause: diagnosis and management. Maturitas. 2021;151:36-40. doi: 10.1016\/j.maturitas.2021.06.014","journal-title":"Maturitas"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T12:21:46Z","timestamp":1712838106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/diagnosis-of-hyperprolactinemia-in-women-a-position-statement-from-the-brazilian-federation-of-gynecology-and-obstetrics-associations-febrasgo-and-the-brazilian-society-of-endocrinology-and-metabol\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":37,"alternative-id":["10.20945\/2359-4292-2023-0502"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0502","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e230502"}}